Lu et al. demonstrate that CD37 is upregulated in AML, and deficiency of CD37 in AML mice model impaired LSC self-renewal and leukemia maintenance in serial transplantation, while CD37 deletion only had a minor effect on normal hematopoiesis, indicating CD37 as a safe and promising target for immunotherapy. This evidence concerns the gene CD37 and acute myeloid leukemia.